ODAN-BENZYDAMINE MOUTHWASH/GARGLE

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Compra

Scheda tecnica Scheda tecnica (SPC)
21-04-2017

Principio attivo:

BENZYDAMINE HYDROCHLORIDE

Commercializzato da:

ODAN LABORATORIES LTD

Codice ATC:

A01AD02

INN (Nome Internazionale):

BENZYDAMINE

Dosaggio:

0.15%

Forma farmaceutica:

MOUTHWASH/GARGLE

Composizione:

BENZYDAMINE HYDROCHLORIDE 0.15%

Via di somministrazione:

BUCCAL

Confezione:

250ML

Tipo di ricetta:

Prescription

Area terapeutica:

MOUTHWASHES AND GARGLES

Dettagli prodotto:

Active ingredient group (AIG) number: 0113801001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2017-04-13

Scheda tecnica

                                _Product Monograph –ODAN-BENZYDAMINE_
_Page 1 of 13_
PRODUCT MONOGRAPH
PR
ODAN-BENZYDAMINE
Benzydamine Mouthwash, BP
benzydamine hydrochloride 1.5 mg/mL (0.15% w/v)
LOCAL ANALGESIC
Odan Laboratories Limited
325 Stillview Avenue
Pointe-Claire, QC,
Canada, H9R 2Y6
Date of Preparation:
April 13, 2017
Submission Control No: 189026
_Product Monograph –ODAN-BENZYDAMINE_
_Page 2 of 13_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
DOSAGE AND ADMINISTRATION
................................................................................4
OVERDOSAGE
..................................................................................................................4
ACTION AND CLINICAL PHARMACOLOGY
..............................................................5
STORAGE AND STABILITY
............................................................................................5
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................5
PART II: SCIENTIFIC INFORMATION
.................................................................................6
PHARMACEUTICAL
INFORMATION............................................................................6
CLINICAL TRIALS
............................................................................................................7
DETAILED PHARMACOLOGY
.......................................................................................7
TOXICOLOGY
.......................................................................................................
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Scheda tecnica Scheda tecnica francese 13-04-2017